AI Insight
The United States pays approximately three to five times more for the same branded prescription drugs compared to most European countries and other high-income nations. In response to concerns about these price disparities representing unfairness in the global pharmaceutical market, President Trump's first administration directed the Centers for Medicare and Medicaid Innovation to benchmark Medicare Part B drug prices to international prices through an international reference pricing system.
Why it matters
This policy experiment could significantly reduce prescription drug costs for Medicare beneficiaries and the US healthcare system by aligning prices with those paid in other developed countries. The approach represents a major shift in US pharmaceutical pricing policy and could influence how the government negotiates drug prices in the future.
Understand the Science
The USA pays substantially more for the same branded drug compared with other high-income nations, with estimates suggesting the USA pays three to five times the price compared with most European countries.1 For many, including the Trump administration, these higher prices represent an unfairness in the global pharmaceutical market. In his first term, US President Donald Trump directed the Centers for Medicare and Medicaid Innovation (CMMI) to benchmark Medicare part B drug prices to international prices as a form of international reference pricing.
Source: [Comment] The US experiments with international reference pricing for prescription drugs